Pembrolizumab and Olaparib (POLAR) Maintenance Therapy in Metastatic Pancreatic Cancer With or Without Homologous Repair Deficiency: A Biomarker Selected Phase II Trial

作者：Wungki Park, Catherine O’Connor, Joanne F. Chou, Marc Hilmi, Zeynep Tarcan, Carly Schwartz, Mary Pat Larsen, Walid K. Chatila, Karthigayini Sivaprakasam, Shigeaki Umeda, Maria Perry, Anna M. Varghese, Kenneth H. Yu, Fiyinfolu Balogun, Alice Zervoudakis, Seth S. Katz, Tae‐Hyung Kim, Ken Zhao, Allison L. Richards, Nicolas Lecomte, Daniel M. Muldoon, Elias-Ramzey Karnoub, Jessica Yang, Imane El-Dika, Devika Rao, Smita Joshi, Michael B. Foote, Ryan Sugarman, James J. Harding, Andrew S. Epstein, David P. Kelsen, Sree B. Chalasani, Fergus Keane, Joshua D. Schoenfeld, Anupriya Singhal, Erin Diguglielmo, Chaitanya Bandlamudi, Junmin Song, Hülya Şahin Özkan, Jungeui Hong, Haochen Zhang, Agustin Cardenas, Maria Lao, Jerry P. Melchor, Ronak Shah, Wenfei Kang, Francesca Mazzoni, Kevin C. Soares, Mark T.A. Donoghue, Vinod P. Balachandran, Mark Schattner, Ernesto Santos, Vineet S. Rolston, Marsha Reyngold, Alice C. Wei, Rami Homsi, Murray J. Tipping, Olca Baştürk, Michael F. Berger, Richard Do, William R. Jarnagin, Nadeem Riaz, Dana Pe’er, Marinela Capanu, Christine A. Iacobuzio–Donahue, Eileen M. O’Reilly · 发表于：Research Square · 年份：2025 · DOI：10.21203/rs.3.rs-7334701/v1 · 被引用次数：3 · 研究领域：Pancreatic and Hepatic Oncology Research、PARP inhibition in cancer therapy、Cancer Genomics and Diagnostics